{"id":"gbcas","safety":{"commonSideEffects":[{"rate":"unknown","effect":"Nephrogenic systemic fibrosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Gadolinium-based contrast agents contain a gadolinium ion that is chelated to a ligand, which is then administered intravenously. The gadolinium ion accumulates in areas with high blood flow and is excreted through the kidneys, providing a contrast between the magnetic properties of tissues and the surrounding environment, allowing for better visualization of internal structures during MRI scans.","oneSentence":"Gadolinium-based contrast agents work by providing a contrast between the magnetic properties of tissues and the surrounding environment, allowing for better visualization of internal structures during MRI scans.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:37:19.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contrast enhancement in MRI scans"}]},"trialDetails":[{"nctId":"NCT07472491","phase":"PHASE2, PHASE3","title":"A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients","status":"NOT_YET_RECRUITING","sponsor":"GE Healthcare","startDate":"2026-03-31","conditions":"Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion","enrollment":640},{"nctId":"NCT04867954","phase":"","title":"Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-10-28","conditions":"Cirrhosis, Liver, Gastroesophageal Varices, Fontan Procedure","enrollment":146},{"nctId":"NCT03331380","phase":"NA","title":"Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-01-05","conditions":"CAD","enrollment":2950},{"nctId":"NCT04373564","phase":"PHASE4","title":"Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years","status":"RECRUITING","sponsor":"Guerbet","startDate":"2021-03-24","conditions":"Motor Function, Cognitive Function, Contrast Media","enrollment":2076},{"nctId":"NCT05915728","phase":"PHASE3","title":"A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-07-24","conditions":"Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology","enrollment":404},{"nctId":"NCT05915702","phase":"PHASE3","title":"A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-07-24","conditions":"Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology","enrollment":303},{"nctId":"NCT06257277","phase":"","title":"An Observational Study to Collect Information on the Safety of Gadolinium-Based Contrast Agents in Patients in India","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-07-08","conditions":"Contrast Enhancement in Magnetic Resonance Imaging","enrollment":150},{"nctId":"NCT04058132","phase":"PHASE2","title":"Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military","status":"TERMINATED","sponsor":"Uniformed Services University of the Health Sciences","startDate":"2019-08-09","conditions":"Traumatic Brain Injury","enrollment":1},{"nctId":"NCT05754476","phase":"","title":"Multi-center Study of Artificial Intelligence Model for Gadolinium-based Contrast Agent Reduction in Brain MRI (MAGNET)","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2019-03-29","conditions":"Brain Diseases","enrollment":3000},{"nctId":"NCT01853163","phase":"NA","title":"Long-Term Retention of Gadolinium in Bone","status":"COMPLETED","sponsor":"Navitas Life Sciences GmbH","startDate":"2013-05-06","conditions":"Focus: Long-term Retention of Gadolinium-based Contrast Agent","enrollment":92},{"nctId":"NCT03455283","phase":"","title":"Post-marketing Safety Study in Participants of All Pathologies Who Receive Gadolinium-Based Contrast Agents (GBCAs) for Contrast-Enhanced Magnetic Resonance Imaging (MR) Examination","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2018-12-17","conditions":"Magnetic Resonance Imaging (MRI)","enrollment":2118}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":672,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GBCAs","genericName":"GBCAs","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gadolinium-based contrast agents work by providing a contrast between the magnetic properties of tissues and the surrounding environment, allowing for better visualization of internal structures during MRI scans. Used for Contrast enhancement in MRI scans.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}